Literature DB >> 10810270

Pathophysiology of lower urinary tract symptoms in aged men without bladder outlet obstruction.

H C Kuo1.   

Abstract

OBJECTIVE: To assess the pathophysiology of lower urinary tract symptoms (LUTS) in aged men without bladder outlet obstruction in a videourodynamic study.
METHODS: In a videourodynamic study of 324 consecutive men with moderate to severe LUTS suggestive for bladder outlet obstruction, 112 were found to be urodynamically nonobstructed. International prostatic symptom score (IPSS), uroflowmetry and transrectal sonography of the prostate were assessed before videourodynamic study. The pressure flow expression and the obstructive parameters were compared between the 212 obstructed and 112 nonobstructed men.
RESULTS: Of the 112 nonobstructed men investigated, 25 had a normal bladder and urethral trace (22.3%), 5 had detrusor instability (4.5%), 17 had a hypersensitive bladder and a normal urethra (15.2%), 3 had detrusor underactivity and a normal urethra (2.7%), while 61 were found to have a poorly relaxed external sphincter and low detrusor contractility (54.5%). Most of the patients in the normal and hypersensitive groups had normal voiding pressure and high flow (NPHF) tracings, whereas men with detrusor underactivity or a poorly relaxed external sphincter had normal voiding pressure and low flow (NPLF) tracings. Only the maximal flow rate and voided volume were significantly higher in patients with NPHF than in patients with NPLF tracings. However, both groups showed a significantly lower IPSS, less residual urine, and a smaller transition zone index than the obstructive group. After medical treatment, 78 patients (69.6%) had satisfactorily improved, 31 patients (27.6%) remained stationary, while 3 (2.7%) worsened.
CONCLUSION: Nonobstructed men with LUTS have various pathophysiologies other than benign prostatic obstruction. In this study 54.5% of these patients had poorly relaxed external sphincter on videourodynamic study. Identification of the underlying pathology can not only prevent unnecessary prostate surgery but can also enable proper medical treatment to be selected. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2000        PMID: 10810270     DOI: 10.1159/000030497

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

Review 1.  Current consensus and controversy on the diagnosis of male lower urinary tract symptoms/benign prostatic hyperplasia.

Authors:  Cheng-Ling Lee; Hann-Chorng Kuo
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2017 Jan-Mar

Review 2.  Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts.

Authors:  Cheng-Ling Lee; Hann-Chorng Kuo
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2017 Apr-Jun

Review 3.  The Therapeutic Effects and Pathophysiology of Botulinum Toxin A on Voiding Dysfunction Due to Urethral Sphincter Dysfunction.

Authors:  Yao-Lin Kao; Kuan-Hsun Huang; Hann-Chorng Kuo; Yin-Chien Ou
Journal:  Toxins (Basel)       Date:  2019-12-13       Impact factor: 4.546

4.  Therapeutic Efficacy of Urethral Sphincteric Botulinum Toxin Injections for Female Sphincter Dysfunctions and a Search for Predictive Factors.

Authors:  Yin-Chien Ou; Kuan-Hsun Huang; Hau-Chern Jan; Hann-Chorng Kuo; Yao-Lin Kao; Kuen-Jer Tsai
Journal:  Toxins (Basel)       Date:  2021-06-02       Impact factor: 4.546

5.  International Prostatic Symptom Score-voiding/storage subscore ratio in association with total prostatic volume and maximum flow rate is diagnostic of bladder outlet-related lower urinary tract dysfunction in men with lower urinary tract symptoms.

Authors:  Yuan-Hong Jiang; Victor Chia-Hsiang Lin; Chun-Hou Liao; Hann-Chorng Kuo
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

Review 6.  Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders-From Bench to Bedside.

Authors:  Yuan-Hong Jiang; Wan-Ru Yu; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2020-03-09       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.